Buy Foundayo (Orforglipron): What It Is and How It Is Supplied in the UK

If you want to buy Foundayo in the UK, the key point is simple: you cannot legally buy it without a prescription. Foundayo is the brand name for orforglipron, a once-daily tablet licensed in the UK for weight management, and the MHRA authorised it on 10 August 2026, making the UK the first country in Europe to do so.

For UK adults looking into prescription weight management treatment, that prescription-only status determines everything about how Foundayo can be supplied, who may be able to use it, and how to avoid unsafe or illegal sellers. Any legitimate supply route involves a clinical assessment by an appropriately qualified prescriber, not a simple over-the-counter purchase.

This page explains what Foundayo is, its licensed uses, how it differs from similar medicines, the clinical evidence behind it, how legal UK supply works, how to check whether an online pharmacy is genuine, current availability, the risks of buying illegally, who it may not suit, and the main side effects and safety points to know before parting with any money.

Key things to know

• Foundayo is the brand name for orforglipron, a once-daily GLP-1 tablet.
• The MHRA authorised it on 10 August 2026 for weight management and for type 2 diabetes.
• It is a prescription-only medicine. It cannot legally be supplied without a prescription.
• Unlike the oral semaglutide tablet, it can be taken at any time of day, with or without food.
• Authorisation is not the same as availability. Supply of a newly licensed medicine takes time to settle.
• Products offered outside the prescription-only supply system may be illegally supplied, unlicensed, falsified or otherwise unsafe, so they should not be used.
• Treatment suitability depends on an individual clinical assessment.

Can you buy Foundayo in the UK?

Not without a prescription. Foundayo is a prescription-only medicine, so it can only be supplied after a prescription has been issued by an appropriately qualified prescriber, following a clinical assessment.

That applies however it is described online. There is no over-the-counter version, no pharmacy-counter version, and no legal route to obtain it without an assessment.

The assessment is not a formality. It exists to establish whether the medicine is appropriate for you, given your medical history, your other conditions and the other medicines you take, and to arrange the monitoring that goes with treatment.

What Foundayo is

Orforglipron is a GLP-1 receptor agonist, meaning it acts on the same pathway as other medicines in that group. Its distinguishing feature is its chemistry: it is a small-molecule, non-peptide medicine, which is why it can be taken as an ordinary tablet without the absorption requirements that peptide-based oral treatments have.

Practically, that means it is taken once a day, at any time of day, with or without food, and without the fasting window and water restrictions that apply to the oral semaglutide tablet.

Like other medicines in this group, the dose is built up in steps rather than starting at the full amount. The specific doses and intervals are in the product information and are set by your prescriber.

What it is licensed for

According to the MHRA, orforglipron is authorised for weight loss and weight maintenance in adults with:

• A BMI of 30 or above, or
• A BMI between 27 and 30 with at least one weight-related health condition

in both cases alongside a reduced-calorie diet and increased physical activity.

It is also authorised to improve blood glucose control in adults with insufficiently controlled type 2 diabetes.

The diet and activity part is in the licensed indication itself, not a footnote. The medicine is authorised as an addition to those changes.

How does Foundayo differ from oral semaglutide?

Foundayo and oral semaglutide are both once-daily oral medicines, but they have different formulations and administration requirements.

Foundayo can be taken once daily at any time of day, without food or water restrictions. Oral semaglutide has specific administration requirements because absorption is affected by food and other medicines.

The medicines have not been compared head to head for weight management, so their results should not be compared by simply taking the highest weight-loss figure from separate trials.

What the evidence showed

The main evidence includes the ATTAIN-1 trial. In this 72-week study, participants receiving the highest studied dose of orforglipron (36 mg) had a mean weight change of −12.4% from baseline, compared with −0.9% with placebo in the intention-to-treat analysis. Participants also received counselling on a healthy diet and physical activity throughout the trial.

What that does and does not tell you

It does tell you that a meaningful average weight change was seen over a long study period, indicating meaningful weight loss at a group level.

It does not tell you what will happen for you. Trial results are averages across a selected population, and individual variation within any such trial is wide. Results vary between individuals.

It does not support comparisons. Orforglipron has not been compared directly with tirzepatide, a once-weekly injection, or with injectable semaglutide in a head-to-head weight management trial, and it has not been compared with the oral semaglutide tablet. Different trials use different participants and protocols, so claims of greater average weight loss across separate studies are not reliable, and we would not present one.

The trial included lifestyle support. As with other medicines in this group, participants were following a reduced-calorie diet and increased physical activity, which is also what the licence specifies.

How legitimate supply works

If Foundayo is appropriate for you, the route is the same as for any prescription weight management medicine or other prescription weight loss medications in the UK, supplied through a regulated weight loss service rather than a simple checkout flow.

What a proper assessment involves

A legitimate online consultation with UK registered prescribers should cover:

• Your medical history, including any personal or family history, and any current or past conditions
• All medicines you currently take, including prescription medicines, over-the-counter medicines and supplements
• Allergies
• Height, weight and BMI, against the licensed criteria
• Previous experience of weight management treatment and what happened
• Whether you are pregnant, breastfeeding or planning a pregnancy

A prescriber then reviews your answers and decides whether treatment is appropriate, which includes being able to decline or ask for more information. If treatment is supplied, there should be a route back for review, monitoring and reporting side effects.

Treatment suitability depends on an individual clinical assessment, and safe decisions about whether you can take Foundayo depend on that assessment. These medicines should only be used under the supervision of an appropriately qualified prescriber.

How to check a pharmacy is registered

Check the supplier rather than the product. Packaging can be copied. A register entry cannot.

1. Search the General Pharmaceutical Council register for the pharmacy, its registration number and trading address, and check they match.
2. Confirm you are asked detailed clinical questions before anything is supplied.
3. Confirm a prescriber reviews your answers, rather than a form simply generating an order.
4. Expect original manufacturer packaging with a patient information leaflet.
5. Expect aftercare, including a way to report side effects and arrange review.

Availability

Authorisation by the MHRA means a medicine may be prescribed and is available in the UK in regulatory terms. It does not mean it is in stock everywhere, and supply of a newly licensed medicine usually takes time to settle across pharmacies.

Check current availability and Foundayo cost directly with a registered pharmacy or prescriber rather than relying on a third-party listing or a search result, since the position changes.

If it is not available when you look, that is not a reason to look outside the regulated system. It is a reason to wait, or to discuss alternatives with a prescriber.

What is being sold without a prescription

When a prescription-only medicine is offered without one, one of three things is happening.

1. A genuine medicine supplied illegally, with no assessment, no monitoring, and no way to know whether it is safe for you.
2. A falsified product, with counterfeit packaging and contents that may not match the label.
3. Something else entirely, sold under a recognisable name.

The MHRA has reported that some illegally supplied weight loss pens were found to contain insulin rather than the labelled medicine, which caused dangerously low blood sugar and hospital admissions in people without diabetes. It has also confirmed that a falsified weight management product reached patients through an online pharmacy in the UK, which shows that professional-looking packaging and a professional-looking website prove nothing.

There is a specific risk with tablets. A tablet is far easier to package convincingly and post than a refrigerated injection pen, so the arrival of oral options creates a new opportunity for illegal sellers.

A weight-management medicine offered without the prescription and clinical assessment required for a prescription-only medicine should not be used. It may be genuine but illegally supplied, falsified, unlicensed or something else entirely, and its quality, contents and storage cannot be assumed to be reliable.

Who it may not be suitable for

Some medical conditions and circumstances require additional assessment or caution before treatment. These include:

• Pregnancy, breastfeeding or plans to become pregnant
• A history of pancreatitis
• Severe gastrointestinal disease
• Certain thyroid or endocrine conditions and relevant family history
• Concomitant diabetes medicines that may increase the risk of hypoglycaemia
• Not meeting the licensed criteria

Your prescriber will consider your individual medical history and medicines before deciding whether Foundayo is appropriate.

Side effects

As with other medicines in this group, the most commonly reported side effects are digestive: nausea, vomiting, diarrhoea and constipation, along with headache and tiredness. They are often more noticeable during dose escalation and may decrease over time.

Some effects are rare but serious. The MHRA has strengthened its warnings about pancreatitis across GLP-1 medicines, following rare reports of necrotising and fatal pancreatitis, and advises seeking urgent medical attention for severe and persistent abdominal pain that may spread through to the back, with or without nausea and vomiting. If pancreatitis is suspected, the MHRA advises that treatment stops immediately and is not restarted if the diagnosis is confirmed.

Your patient information leaflet lists every reported effect for your specific medicine, with how often it occurs.

Pregnancy and contraception

Foundayo should not be used during pregnancy or breastfeeding. If you are planning a pregnancy, the Foundayo product information advises stopping orforglipron at least 3 weeks before the planned pregnancy.

Women who could become pregnant should use effective contraception while taking Foundayo.

Foundayo may also reduce the effectiveness of oral hormonal contraceptives. The product information advises using a non-oral contraceptive method or adding a barrier method for 30 days after starting Foundayo and for 30 days after each dose increase. Speak to your prescriber if you use the contraceptive pill.

Red flags: when to seek urgent help

• Severe and persistent stomach pain that may spread through to your back, with or without nausea and vomiting
• Swelling of the face, lips, tongue or throat, or difficulty breathing
• Signs of significant dehydration, including passing very little urine, marked dizziness and unusual drowsiness
• Symptoms of low blood sugar, particularly if you take insulin or a sulfonylurea

Contact your prescriber promptly for persistent vomiting or diarrhoea, pain in the upper right abdomen particularly after eating, or side effects that are not settling.

If you have taken a product obtained without a prescription and feel unwell, seek medical advice and say what you took. Clinicians need the information, not an explanation.

If you are considering it

For people who prefer an oral treatment, Foundayo offers a different way to take a GLP-1 medicine because it does not require an injection or the fasting and water restrictions associated with oral semaglutide.

The important step is still the clinical assessment. A prescriber can determine whether Foundayo is appropriate for you, consider other medicines or health conditions, explain how treatment is started and monitored, and discuss what to do if side effects occur.

Medical Disclaimer

This article is for general information only. It is not medical advice, it is not a complete list of side effects, and it does not replace the patient information leaflet supplied with your medicine or an individual assessment by an appropriately qualified healthcare professional.

Foundayo is a prescription-only medicine. It should only be used under the supervision of an appropriately qualified prescriber, following a clinical assessment that considers your medical history, current medicines and other conditions. Treatment suitability depends on an individual clinical assessment, and results vary between individuals. Trial results described here are averages from a specific study population and cannot predict an individual outcome.

Do not obtain prescription medicines outside the regulated system. Products supplied that way are not covered by MHRA oversight and their contents, strength and storage cannot be relied upon.

Seek urgent medical attention for severe and persistent stomach pain that may spread to your back, swelling of the face, lips, tongue or throat, difficulty breathing, or signs of significant dehydration. Suspected side effects can be reported through the Yellow Card scheme, which the MHRA uses to monitor the safety of medicines.